National Institute for Health and Care Excellence: Standards

Department of Health and Social Care written question – answered on 7th June 2022.

Alert me about debates like this

Photo of Lord Hunt of Kings Heath Lord Hunt of Kings Heath Labour

To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 May (HL147), how the National Institute for Health and Care Excellence (NICE) appraisals of (1) Sacituzumab govitecan (Trodelvy), and (2) Tucatinib (Tukysa) with trastuzumab and capecitabine, were included in the statistic cited as 100 per cent of guidance of new medicines being issued within three months of a licence in 2021/22, where NICE proceeded to appraisal.

Photo of Lord Kamall Lord Kamall The Parliamentary Under-Secretary for Health and Social Care

The appraisal of sacituzumab govitecan is not included in this statistic as the National Institute for Health and Care Excellence (NICE) has not yet issued its final guidance. The appraisal of tucatinib is not recorded by the timeliness metric for 2021/22 as NICE’s final guidance was issued in the 2022/23 business year.

NICE issued final guidance within 90 days of licensing for 100% of published appraisals of new active substances where timelines were within NICE’s control. Topics outside of this timeframe were impacted by external factors such as where a company requested a delay to NICE’s evaluation.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.